NCT02875093View on ClinicalTrials.gov

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

PHASE1TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 20, 2017

Primary Completion Date

July 10, 2019

Study Completion Date

July 10, 2019

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

ADI-PEG 20

Investigational Medicine

DRUG

Cytarabine

low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days

Trial Locations (3)

704

National Cheng Kung University Hospital, Tainan City

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

33305

Chang Gung Memorial Hospital - Linkou, Taoyuan District

Sponsors

Lead Sponsor

Polaris Group
All Listed Sponsors
lead

Polaris Group

INDUSTRY